Biello K B, Edeza A, Salhaney P, Biancarelli D L, Mimiaga M J, Drainoni M L, Childs E S, Bazzi A R
a Departments of Behavioral & Social Health Sciences and Epidemiology, Brown University School of Public Health , Providence , RI , USA.
b Center for Health Equity Research, Brown University , Providence , RI , USA.
AIDS Care. 2019 Oct;31(10):1214-1220. doi: 10.1080/09540121.2019.1587356. Epub 2019 Mar 1.
The efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention has been established among people who inject drugs (PWID). HIV uninfected, at risk PWID, could likely benefit from long-acting injectable formulations of PrEP ("LAI-PrEP"); however, its acceptability in this population has not been previously documented. Thirty-three HIV-uninfected PWID in the U.S. Northeast completed an in-depth interview regarding perceived acceptability of LAI-PrEP. Coded data were synthesized using deductive thematic analysis. The majority of PWID interviewed believed LAI-PrEP would be acceptable. Participants perceived that receiving injections every two months would reduce barriers to daily oral PrEP adherence, including forgetting while "high" and safeguarding pills when homeless. A few participants expressed concerns regarding LAI-PrEP, including medical mistrust, a concern that injections could alter their "high" or be "triggering" for PWID. LAI-PrEP has the potential to reduce HIV among PWID; however, their perspectives are largely absent from research examining its efficacy, representing a missed opportunity.
暴露前预防(PrEP)对预防注射吸毒者(PWID)感染艾滋病毒的有效性已得到证实。未感染艾滋病毒、有感染风险的注射吸毒者可能会从长效注射用PrEP(“LAI-PrEP”)中受益;然而,此前尚未有文献记载其在该人群中的可接受性。美国东北部的33名未感染艾滋病毒的注射吸毒者就LAI-PrEP的可感知可接受性完成了一次深入访谈。使用演绎主题分析法对编码数据进行了综合分析。大多数接受访谈的注射吸毒者认为LAI-PrEP是可以接受的。参与者认为每两个月接受一次注射将减少每日口服PrEP依从性的障碍,包括在“吸毒兴奋”时忘记服药以及在无家可归时保护药丸。一些参与者对LAI-PrEP表示担忧,包括对医疗的不信任、担心注射会改变他们的“吸毒兴奋”状态或对注射吸毒者产生“触发作用”。LAI-PrEP有降低注射吸毒者感染艾滋病毒的可能性;然而,在研究其有效性时很大程度上没有考虑他们的观点,这是一个错失的机会。